Dawei Wang1,2, Xiaohu Shao1, Qiang Wang1, Xiaohong Pan1, Yujun Dai1, Shuxian Yao1, Tong Yin1,2, Zhugang Wang3, Jiang Zhu1, Xiaodong Xi1, Zhu Chen1,2, Saijuan Chen1,2, Guowei Zhang1,4. 1. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, SJTU, Shanghai, China. 2. National Research Center for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3. Shanghai Research Center for Model Organisms, Shanghai, China. 4. Key Laboratory of Aging and Cancer Biology of Zhejiang Province, Department of Basic Medical Sciences, Hangzhou Normal University School of Medicine, Hangzhou, Zhejiang Province, China.
Abstract
BACKGROUND: Treatment of hemophiliacs with inhibitors remains challenging, and new treatments are in urgent need. Coagulation factor X plays a critical role in the downstream of blood coagulation cascade, which could serve as a bypassing agent for hemophilia therapy. Base on platelet-targeted gene therapy for hemophilia by our and other groups, we hypothesized that activated factor X (FXa) targeted stored in platelets might be effective in treating hemophilia A (HA) and B (HB) with or without inhibitors. METHODS: To achieve the storage of FXa in platelets, we constructed a FXa precursor and used the integrin αIIb promoter to control the targeted expression of FXa precursor in platelets. The expression cassette (2bFXa) was carried by lentivirus and introduced into mouse hematopoietic stem and progenitor cells (HSPCs), which were then transplanted into HA and HB mice. FXa expression and storage in platelets was examined in vitro and in vivo. We evaluated the therapeutic efficacy of platelet-stored FXa by tail bleeding assays and the thrombelastography. In addition, thrombotic risk was assessed in the recipient mice and the lipopolysaccharide induced inflammation mice. RESULTS: By transplanting 2bFXa lentivirus-transduced HSPCs into HA and HB mice, FXa was observed stably stored in platelet α-granules, the stored FXa is releasable and functional upon platelet activation. The platelet-stored FXa can significantly ameliorate bleeding phenotype in HA and HB mice as well as the mice with inhibitors. Meanwhile, no FXa leakage in plasma and no signs of increased risk of hypercoagulability were found in transplantation recipients and lipopolysaccharide induced septicemia recipients. CONCLUSIONS: Our proof-of-principle data indicated that target expression of the FXa precursor to platelets can generate a storage pool of FXa in platelet α-granules, the platelet-stored FXa is effective in treating HA and HB with inhibitors, suggesting that this could be a novel choice for hemophilia patients with inhibitors.
BACKGROUND: Treatment of hemophiliacs with inhibitors remains challenging, and new treatments are in urgent need. Coagulation factor X plays a critical role in the downstream of blood coagulation cascade, which could serve as a bypassing agent for hemophilia therapy. Base on platelet-targeted gene therapy for hemophilia by our and other groups, we hypothesized that activated factor X (FXa) targeted stored in platelets might be effective in treating hemophilia A (HA) and B (HB) with or without inhibitors. METHODS: To achieve the storage of FXa in platelets, we constructed a FXa precursor and used the integrin αIIb promoter to control the targeted expression of FXa precursor in platelets. The expression cassette (2bFXa) was carried by lentivirus and introduced into mouse hematopoietic stem and progenitor cells (HSPCs), which were then transplanted into HA and HB mice. FXa expression and storage in platelets was examined in vitro and in vivo. We evaluated the therapeutic efficacy of platelet-stored FXa by tail bleeding assays and the thrombelastography. In addition, thrombotic risk was assessed in the recipient mice and the lipopolysaccharide induced inflammation mice. RESULTS: By transplanting 2bFXa lentivirus-transduced HSPCs into HA and HB mice, FXa was observed stably stored in platelet α-granules, the stored FXa is releasable and functional upon platelet activation. The platelet-stored FXa can significantly ameliorate bleeding phenotype in HA and HB mice as well as the mice with inhibitors. Meanwhile, no FXa leakage in plasma and no signs of increased risk of hypercoagulability were found in transplantation recipients and lipopolysaccharide induced septicemia recipients. CONCLUSIONS: Our proof-of-principle data indicated that target expression of the FXa precursor to platelets can generate a storage pool of FXa in platelet α-granules, the platelet-stored FXa is effective in treating HA and HB with inhibitors, suggesting that this could be a novel choice for hemophilia patients with inhibitors.
Authors: Johannes Oldenburg; Johnny N Mahlangu; Benjamin Kim; Christophe Schmitt; Michael U Callaghan; Guy Young; Elena Santagostino; Rebecca Kruse-Jarres; Claude Negrier; Craig Kessler; Nancy Valente; Elina Asikanius; Gallia G Levy; Jerzy Windyga; Midori Shima Journal: N Engl J Med Date: 2017-07-10 Impact factor: 91.245
Authors: Qizhen Shi; David A Wilcox; Scot A Fahs; Hartmut Weiler; Clive W Wells; Brian C Cooley; Drashti Desai; Patricia A Morateck; Jack Gorski; Robert R Montgomery Journal: J Clin Invest Date: 2006-07 Impact factor: 14.808
Authors: Johnny Mahlangu; Johannes Oldenburg; Ido Paz-Priel; Claude Negrier; Markus Niggli; M Elisa Mancuso; Christophe Schmitt; Victor Jiménez-Yuste; Christine Kempton; Christophe Dhalluin; Michael U Callaghan; Willem Bujan; Midori Shima; Joanne I Adamkewicz; Elina Asikanius; Gallia G Levy; Rebecca Kruse-Jarres Journal: N Engl J Med Date: 2018-08-30 Impact factor: 91.245
Authors: Lindsey A George; Spencer K Sullivan; Adam Giermasz; John E J Rasko; Benjamin J Samelson-Jones; Jonathan Ducore; Adam Cuker; Lisa M Sullivan; Suvankar Majumdar; Jerome Teitel; Catherine E McGuinn; Margaret V Ragni; Alvin Y Luk; Daniel Hui; J Fraser Wright; Yifeng Chen; Yun Liu; Katie Wachtel; Angela Winters; Stefan Tiefenbacher; Valder R Arruda; Johannes C M van der Loo; Olga Zelenaia; Daniel Takefman; Marcus E Carr; Linda B Couto; Xavier M Anguela; Katherine A High Journal: N Engl J Med Date: 2017-12-07 Impact factor: 91.245
Authors: Mikael Tranholm; Kim Kristensen; Annemarie T Kristensen; Charles Pyke; Rasmus Røjkjaer; Egon Persson Journal: Blood Date: 2003-07-17 Impact factor: 22.113
Authors: Suk See De Ravin; Xiaolin Wu; Susan Moir; Sandra Anaya-O'Brien; Nana Kwatemaa; Patricia Littel; Narda Theobald; Uimook Choi; Ling Su; Martha Marquesen; Dianne Hilligoss; Janet Lee; Clarissa M Buckner; Kol A Zarember; Geraldine O'Connor; Daniel McVicar; Douglas Kuhns; Robert E Throm; Sheng Zhou; Luigi D Notarangelo; I Celine Hanson; Mort J Cowan; Elizabeth Kang; Coleen Hadigan; Michael Meagher; John T Gray; Brian P Sorrentino; Harry L Malech Journal: Sci Transl Med Date: 2016-04-20 Impact factor: 17.956